Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 3, pp. 431-442
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice
Giuseppe Cabibbo, Ciro Celsa, Lorenza Rimassa, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 957-966
Open Access | Times Cited: 21
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
Fabio Piscaglia, Gianluca Masi, Erika Martinelli, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104110-104110
Closed Access | Times Cited: 3
Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges
Lily Dara, Eleonora De Martin
Liver International (2025) Vol. 45, Iss. 2
Open Access | Times Cited: 2
Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide
Vishnu Nagalapuram, Niveditha Popuri, Ryan David Nipp, et al.
JCO Oncology Practice (2025)
Closed Access | Times Cited: 2
Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation
Michael Li, Sherrie Bhoori, Neil Mehta, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 743-755
Closed Access | Times Cited: 16
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
Hepatology (2024)
Closed Access | Times Cited: 10
The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy
Jingzhong Ouyang, Yi Yang, Yanzhao Zhou, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1519-1531
Closed Access | Times Cited: 12
The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors
Zhen-Xin Zeng, Jiayi Wu, Junyi Wu, et al.
Hepatology International (2023) Vol. 18, Iss. 2, pp. 651-660
Closed Access | Times Cited: 11
Cirrhosis and complications hepatocellular carcinoma – expanding indications for immunotherapy
Helena Degroote
Acta Clinica Belgica (2025), pp. 1-7
Closed Access
MoS2 Nanozyme–Chlorella Hydrogels: Pioneering a Hepatocellular Carcinoma Integrative Therapy
Mengya Zhang, Jingsheng Zhou, Xianghe Jiang, et al.
Advanced Functional Materials (2025)
Closed Access
Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
Dengyong Zhang, Yan Zhu, Zhengchao Shen, et al.
Seminars in Cancer Biology (2025) Vol. 111, pp. 60-75
Closed Access
Inflammation and cancer: molecular mechanisms and clinical consequences
Hikmet Akkız, Cem Şimşek, Deniz Balcı, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma
Jianlin Lu, Yuan Cheng, Zi-Ling Xu, et al.
World Journal of Gastrointestinal Oncology (2025) Vol. 17, Iss. 4
Closed Access
Research status and frontiers in liver cancer immunotherapy: a bibliometric perspective on highly cited literature
Pan Su, Yongkai Han, Jindong Yi, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors
M. Sayer, Hirofumi Hamano, Misako Nagasaka, et al.
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access
Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction
Matthias Pinter, Claudia Angela Maria Fulgenzi, David J. Pinato, et al.
Gut (2025), pp. gutjnl-334928
Closed Access
irLI or not irLI: That is the question
Lucy Meunier, Eléonora De Martin, Yves Horsmans, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 1, pp. e30-e32
Closed Access | Times Cited: 3
Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives
Valeria De Gaetano, Maria Pallozzi, Lucia Cerrito, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1388-1388
Open Access | Times Cited: 3
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Eléonora De Martin, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Gut (2024), pp. gutjnl-332125
Closed Access | Times Cited: 3
A bibliometric and visual analysis based on immune checkpoint inhibitors for hepatocellular carcinoma: 2014 – 2024
Gao‐Min Liu, Rui Guo, Jiwei Xu
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Cardiological Adverse Events in Hepatocellular Carcinoma Patients Receiving Immunotherapy: Influence of Comorbidities and Clinical Outcomes
Marta Fortuny, Marta García Calonge, Óscar Arrabal, et al.
European Journal of Cancer (2025), pp. 115404-115404
Closed Access
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of …
Giuseppe Cabibbo, Bruno Daniele, Mauro Borzio, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 3, pp. 394-405
Open Access | Times Cited: 9
Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma
Hiroyuki Suzuki, Hideki Iwamoto, Toshimitsu Tanaka, et al.
Hepatology International (2023) Vol. 18, Iss. 2, pp. 610-622
Open Access | Times Cited: 8
New Scenarios in Liver Transplantation for Hepatocellular Carcinoma
Ezequiel Mauro, Manuel Rodríguez‐Perálvarez, Antonio D’Alessio, et al.
Liver International (2024)
Open Access | Times Cited: 2
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management
Evangelos Triantafyllou, Cathrin Gudd, Lucia Possamai
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top